CRDF Cardiff Oncology, Inc.
Legal ·
Cardiff Oncology settled its lawsuit against Nerviano Medical Sciences, the licensor of its lead drug onvansertib, on September 14, 2026. The case is dismissed with prejudice and the license is amended. Nerviano was the only defendant in the suit.
Nerviano Medical Sciences told Cardiff on May 27, 2026 it was ending the License Agreement over a patent inventorship dispute. Cardiff, which sued NMS as defendant on May 19, says the notice is legally ineffective.
The company is selling 15,384,619 shares. The stock last traded at $2.44 on December 9, 2024. Cardiff plans to use proceeds for onvansertib trials in colorectal cancer.
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | -$45.9 million | -$45.4 million |
| Cash from operations | -$37.9 million | -$37.7 million |
| Cash and equivalents | $17.5 million | $51.5 million |
| Short-term investments | $40.8 million | $40.3 million |
Our latest story on this, dated Dec 10, 2024: "Cardiff Oncology prices $40 million share offering at $2.60, above last sale". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 14, 2026: "Cardiff Oncology settles onvansertib license lawsuit with Nerviano Medical Sciences". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 14, 2026: "Cardiff Oncology settles onvansertib license lawsuit with Nerviano Medical Sciences". The story links the filing or release it is based on. Read the story.
Cardiff Oncology, Inc. trades under the ticker CRDF on NASDAQ.
Cardiff Oncology, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Cardiff Oncology, Inc. is 1213037. Its filings are on SEC EDGAR.
77,795,249 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Cardiff Oncology, Inc. under United States.
Our directory classifies Cardiff Oncology, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Cardiff Oncology, Inc. is US14147L1089.
aibio.space lists Cardiff Oncology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Cardiff Oncology, Inc. reported a net loss of $45.9 million for the fiscal year ended Dec 31, 2025, and used $37.9 million of cash in operations, per its annual report to the SEC.
$34.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Cardiff Oncology, dated Sep 14, 2026: "Cardiff Oncology settles onvansertib license lawsuit with Nerviano Medical Sciences". Cardiff Oncology settled its lawsuit against Nerviano Medical Sciences, the licensor of its lead drug onvansertib, on September 14, 2026. The case is dismissed with prejudice and the license is amended. Nerviano was the only defendant in the suit. Source.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio